Various malignancies where the mutation rate of Smad2 occurs at a low frequency are non small cell lung carcinoma (NSCLC) 2%, hepatocellular carcinoma (HCC) 3%, colorectal cancer 8% and cervical cancers 8% (Kim et al., 2000). This evidence concerns the gene SMAD2 and non-small cell lung carcinoma.